Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statement of Changes in Stockholders' (Deficit) Equity

v3.19.3.a.u2
Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($)
Total
Fiscal Year To Date
Preferred Stock [Member]
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Beginning balance at May. 31, 2018 $ (13,157,971) $ (13,157,971) $ 92 $ 216,881 $ (159) $ 159,764,611 $ (173,139,396)
Beginning balance, shares at May. 31, 2018     92,100 216,881,790 159,011    
Acquisition of ProstaGene LLC 0 0 $ 0 $ 0 $ 0 0 0
Acquisition of ProstaGene LLC, shares     0 0 0    
Issuance of stock payment shares 0 0 $ 0 $ 0 $ 0 0 0
Issuance of stock payment shares, shares     0 0 0    
Issuance of stock for note payable redemption 0 0 $ 0 $ 0 $ 0 0 0
Issuance of stock for note payable redemption ,shares     0 0 0    
Proceeds from registered direct offering 985,000 985,000 $ 0 $ 1,970 $ 0 983,030 0
Proceeds from registered direct offering, shares     0 1,970,000 0    
Offering costs related to registered direct offering, value (75,151) (75,151) $ 0 $ 0 $ 0 (75,151) 0
Offering costs related to registered direct offering, shares     0 0 0    
Proceeds from private equity offering 7,514,300 7,514,300 $ 0 $ 15,029 $ 0 7,499,271 0
Proceeds from private equity offering, shares     0 15,028,600 0    
Offering costs related to private equity offering (882,716) (882,716) $ 0 $ 0 $ 0 (882,716) 0
Offering costs related to debt offering 0 0 0 0 0 0 0
Debt discount and issuance costs related to offering 0 0 0 0 0 0 0
Beneficial conversion feature on note payable and relative fair value associated with warrants 0 0 0 0 0 0 0
Legal fees in connection with equity offerings (50,544) (50,544) 0 0 0 (50,544) 0
Offering costs related to public warrant tender offers (882,716)            
Stock-based compensation 283,346 283,346 0 0 0 283,346 0
Net loss (14,413,569) (14,413,569) 0 0 0 0 (14,413,569)
Ending balance at Aug. 31, 2018 (19,797,305) (19,797,305) $ 92 $ 233,880 $ (159) 167,521,847 (187,552,965)
Ending balance, shares at Aug. 31, 2018     92,100 233,880,390 159,011    
Beginning balance at May. 31, 2018 (13,157,971) (13,157,971) $ 92 $ 216,881 $ (159) 159,764,611 (173,139,396)
Beginning balance, shares at May. 31, 2018     92,100 216,881,790 159,011    
Net loss (28,718,950)            
Ending balance at Nov. 30, 2018 (8,063,924) (8,063,924) $ 92 $ 290,810 $ (159) 193,503,678 (201,858,345)
Ending balance, shares at Nov. 30, 2018     92,100 290,808,960 159,011    
Beginning balance at Aug. 31, 2018 (19,797,305) (19,797,305) $ 92 $ 233,880 $ (159) 167,521,847 (187,552,965)
Beginning balance, shares at Aug. 31, 2018     92,100 233,880,390 159,011    
Acquisition of ProstaGene LLC 11,558,000 11,558,000 $ 0 $ 18,658 $ 0 11,539,342 0
Acquisition of ProstaGene LLC, shares     0 18,658,000 0    
Issuance of stock payment shares 0 8,342 $ 0 $ 8,342 $ 0 (8,342) 0
Issuance of stock payment shares, shares     0 8,342,000 0    
Issuance of stock for note payable redemption 0 0 $ 0 $ 0 $ 0 0 0
Issuance of stock for note payable redemption ,shares     0 0 0    
Proceeds from registered direct offering 0 985,000 $ 0 $ 0 $ 0 0 0
Proceeds from registered direct offering, shares     0 0 0    
Offering costs related to registered direct offering, value 0 (75,151) $ 0 $ 0 $ 0 0 0
Offering costs related to registered direct offering, shares     0 0 0    
Proceeds from private equity offering 14,964,285 22,478,585 $ 0 $ 29,930 $ 0 14,934,355 0
Proceeds from private equity offering, shares     0 29,928,570 0    
Offering costs related to private equity offering (1,693,354) (2,576,070) $ 0 $ 0 $ 0 (1,693,354) 0
Offering costs related to debt offering 0 0 0 0 0 0 0
Debt discount and issuance costs related to offering 0 0 0 0 0 0 0
Beneficial conversion feature on note payable and relative fair value associated with warrants 0 0 0 0 0 0 0
Legal fees in connection with equity offerings (25,652) (76,195) 0 0 0 (25,652) 0
Stock-based compensation 1,227,140 1,510,486 0 0 0 1,227,140 0
Net loss (14,305,380) (28,718,950) 0 0 0   (14,305,380)
Ending balance at Nov. 30, 2018 (8,063,924) (8,063,924) $ 92 $ 290,810 $ (159) 193,503,678 (201,858,345)
Ending balance, shares at Nov. 30, 2018     92,100 290,808,960 159,011    
Issuance of stock payment shares     $ 0   $ 0    
Issuance of stock payment shares, shares     0   0    
Proceeds from registered direct offering     $ 0 $ 10,728 $ 0    
Proceeds from registered direct offering, shares     0 10,728,480 0    
Offering costs related to registered direct offering, value     $ 0 $ 0 $ 0    
Offering costs related to registered direct offering, shares     0 0 0    
Proceeds from public warrant tender offers     $ 0 $ 2,018 $ 0    
Proceeds from public warrant tender offers (shares)     0 2,018,000 0    
Inducement interest expense - public warrant tender offers 0            
Offering costs related to Series C Preffered offering     $ 0 $ 0 $ 0    
Legal fees in connection with equity offerings     0 0 0    
Offering costs related to public warrant tender offers (121,079)   0        
Stock-based compensation     0 0 0    
Net loss     0 0 0    
Ending balance at Feb. 28, 2019     $ 92 $ 304,680 $ (159)    
Ending balance, shares at Feb. 28, 2019     92,100 304,679,081 159,011    
Proceeds from registered direct offering     $ 0 $ 10,931 $ 0    
Proceeds from registered direct offering, shares     0 10,931,000 0    
Proceeds from private equity offering     $ 0 $ 0 $ 0    
Proceeds from private equity offering, shares     0 0 0    
Offering costs related to private equity offering     $ 0 $ 0 $ 0    
Proceeds from Series C Convertible Preferred offering     $ 3        
Proceeds from Series C Convertible Preferred offering, shares     3,246        
Dividends on Series C Convertible Preferred shares (37,351)   $ 0 0 0    
Legal fees in connection with equity offerings     0 0 0    
Offering costs related to public warrant tender offers 0            
Stock-based compensation     0 0 0    
Net loss     0 0 0    
Ending balance at May. 31, 2019 (8,914,060) (8,914,060) $ 95 $ 329,555 $ (159) 220,119,856 (229,363,407)
Ending balance, shares at May. 31, 2019     95,346 329,554,763 159,011    
Issuance of stock for note payable redemption 1,005,000 1,005,000 $ 0 $ 3,015 $ 0 1,001,985 0
Issuance of stock for note payable redemption ,shares     0 3,014,181 0    
Proceeds from registered direct offering 2,255,800 2,255,800 $ 0 $ 5,640 $ 0 2,250,160 0
Proceeds from registered direct offering, shares       5,639,500      
Offering costs related to registered direct offering, value (260,208) (260,208) $ 0 $ 0 $ 0 (260,208) 0
Offering costs related to registered direct offering, shares     0 0 0    
Proceeds from public warrant tender offers 11,900,260 11,900,260 $ 0 $ 45,376 $ 0 11,854,884 0
Proceeds from public warrant tender offers (shares)     0 45,375,923 0    
Proceeds from Series C Convertible Preferred offering 1,754,000 1,754,000 $ 2     1,753,998 0
Proceeds from Series C Convertible Preferred offering, shares     1,754        
Offering costs related to Series C Preffered offering (197,460) (197,460) $ 0 $ 0 $ 0 (197,460) 0
Dividends on Series C Convertible Preferred shares (110,826) (110,826) 0 0 0 0 (110,826)
Legal fees in connection with equity offerings (15,877) (15,877) 0 0 0 (15,877) 0
Offering costs related to public warrant tender offers (1,058,466) (1,058,466) 0     (1,058,466) 0
Stock-based compensation 580,727 580,727 0 0 0 580,727 0
Note conversion and extension fees, Value 0 0 0 $ 0 $ 0 0 0
Note conversion and extension fees, Shares       0 0    
Exercise of option to repurchase common stock 0 0          
Inducement interest expense - debt conversion 2,430,514 2,430,514 0 $ 0 $ 0 2,430,514 0
Net loss (16,163,999) (16,163,999) 0 0 0 0 (16,163,999)
Ending balance at Aug. 31, 2019 (6,794,595) (6,794,595) $ 97 $ 383,586 $ (159) 238,460,113 (245,638,232)
Ending balance, shares at Aug. 31, 2019     97,100 383,584,367 159,011    
Beginning balance at May. 31, 2019 (8,914,060) (8,914,060) $ 95 $ 329,555 $ (159) 220,119,856 (229,363,407)
Beginning balance, shares at May. 31, 2019     95,346 329,554,763 159,011    
Net loss (31,024,467)            
Ending balance at Nov. 30, 2019 (13,631,597) (13,631,597) $ 100 $ 399,316 $ (159) 246,618,030 (260,648,884)
Ending balance, shares at Nov. 30, 2019     99,888 399,315,351 159,011    
Beginning balance at Aug. 31, 2019 (6,794,595) (6,794,595) $ 97 $ 383,586 $ (159) 238,460,113 (245,638,232)
Beginning balance, shares at Aug. 31, 2019     97,100 383,584,367 159,011    
Issuance of stock for note payable redemption 739,959 1,744,959 $ 0 $ 2,269 $ 0 737,690 0
Issuance of stock for note payable redemption ,shares       2,270,151      
Proceeds from registered direct offering 4,409,500 6,665,300 $ 0 $ 13,461 $ 0 4,396,039 0
Proceeds from registered direct offering, shares     0 13,460,833 0    
Offering costs related to registered direct offering, value (73,690) (333,898) $ 0 $ 0 $ 0 (73,690) 0
Offering costs related to registered direct offering, shares     0 0 0    
Proceeds from public warrant tender offers 0 11,900,260 $ 0 $ 0 $ 0 0 0
Proceeds from public warrant tender offers (shares)     0 0 0    
Proceeds from Series C Convertible Preferred offering 2,788,000 4,542,000 $ 3 $ 0 $ 0 2,787,997 0
Proceeds from Series C Convertible Preferred offering, shares     2,788 0 0    
Offering costs related to Series C Preffered offering (181,722) (379,182) $ 0 $ 0 $ 0 (181,722) 0
Dividends on Series C Convertible Preferred shares (150,184) (261,010) 0 0 0 0 (150,184)
Legal fees in connection with equity offerings 0 (15,877) 0 0 0 0 0
Offering costs related to public warrant tender offers 0 (1,058,466) 0 0 0 0 0
Stock-based compensation 434,245 1,014,972 0 0 0 434,245 0
Note conversion and extension fees, Value (216,800) (216,800) $ 0 $ 0 $ 0 (216,800) 0
Note conversion and extension fees, Shares     0 0 0    
Exercise of option to repurchase common stock (8,342) (8,342) $ 0 $ 0 $ 0 (8,342) 0
Inducement interest expense - debt conversion 282,500 2,713,014 0 0 0 282,500 0
Net loss (14,860,468) (31,024,467) 0 0 0 0 (14,860,468)
Ending balance at Nov. 30, 2019 $ (13,631,597) $ (13,631,597) $ 100 $ 399,316 $ (159) $ 246,618,030 $ (260,648,884)
Ending balance, shares at Nov. 30, 2019     99,888 399,315,351 159,011